Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (NRIX) is a clinical-stage biopharmaceutical leader developing targeted protein degradation therapies for cancer and immune disorders. This page provides centralized access to official news and press releases, offering critical insights into the company’scientific advancements and strategic direction.
Investors and researchers will find updates on clinical trial progress, regulatory milestones, and strategic collaborations with industry partners. The resource covers Nurix’s innovative pipeline, including BTK degraders for oncology and CBL-B inhibitors for immune modulation, alongside financial developments and operational updates.
Content is organized to highlight therapeutic innovations, scientific publications, and partnership announcements, ensuring stakeholders stay informed about Nurix’s progress in advancing oral small molecule therapies. Bookmark this page for real-time updates on Nurix’s pioneering work in E3 ligase modulation and protein homeostasis.
Nurix Therapeutics (NRIX) presented positive preclinical data at AACR 2025 for multiple orally available, brain-penetrant protein degraders targeting three oncology targets. Bexobrutideg, their lead BTK degrader, demonstrated exceptional efficiency by degrading approximately 10,000 BTK copies per hour at clinically relevant concentrations.
The company showcased NRX-0305, a BRAF degrader effective across all three BRAF mutation classes while sparing healthy cells. It showed superior anti-tumor efficacy in resistant tumors compared to competitor CFT1946 and demonstrated effectiveness in combination with MEKi.
Additionally, Nurix presented data on NRX-4972, an orally bioavailable Aurora A kinase degrader developed in collaboration with Alex's Lemonade Stand Foundation. This degrader showed significant efficacy in neuroblastoma models, inducing DNA damage, apoptosis, and G2/M arrest more effectively than traditional inhibitors.
Nurix Therapeutics (NRIX) announced FDA clearance of their IND application for GS-6791/NX-0479, a novel IRAK4 degrader developed for inflammatory conditions. The Phase 1 trial is set to begin in Q2 2025, focusing on single and multiple ascending dose studies in healthy volunteers.
The development triggers a $5 million milestone payment from collaboration partner Gilead Sciences, bringing total payments under their 2019 agreement to $135 million. Nurix remains eligible for additional $420 million in milestones plus potential royalties.
GS-6791/NX-0479 has shown promising preclinical results, demonstrating rapid IRAK4 degradation across multiple human cell types and robust efficacy in arthritis models. The drug targets inflammatory conditions including rheumatoid arthritis and atopic dermatitis. Nurix retains the option to co-develop and co-detail in the US, with a 50/50 split of profits and losses.
Nurix Therapeutics (NRIX) has granted inducement awards to 16 new employees on April 8, 2025, as part of their 2024 Equity Inducement Plan. The awards include:
- Stock options to purchase 79,950 shares with a 10-year term at $9.26 per share exercise price
- Restricted stock units (RSUs) representing 54,750 shares
The stock options vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. RSUs also vest over 4 years, with 25% vesting on April 30, 2026, and the remainder vesting quarterly. Both awards require continued employment with Nurix for vesting.
Nurix Therapeutics (NRIX) reported Q1 2025 financial results and corporate updates. The company's lead BTK degrader NX-5948 received the nonproprietary name 'bexobrutideg' and FDA Orphan Drug Designation for Waldenström macroglobulinemia. Revenue increased to $18.5M from $16.6M year-over-year, including $7M in Sanofi collaboration milestones.
The company achieved significant milestones, including a $15M license extension fee from Sanofi and strengthened its leadership with Roy D. Baynes joining the board and John Northcott as chief commercial officer. R&D expenses rose to $69.7M from $50.0M, while G&A expenses slightly decreased to $11.7M.
The company reported a net loss of $56.4M ($0.67 per share) compared to $41.5M ($0.76 per share) in the previous year. Nurix maintains a strong financial position with $549.7M in cash and marketable securities, excluding recent milestone payments.
Nurix Therapeutics (NRIX) has licensed an undisclosed drug discovery program to Sanofi targeting a novel transcription factor for autoimmune diseases. The target, distinct from their STAT6 program, is a central regulator of inflammation identified using Nurix's DEL-AI platform.
The deal brings $15 million in license extension fees to Nurix, totaling $105 million received from Sanofi to date under their 2019 collaboration agreement. Nurix remains eligible for up to $465 million in additional milestone payments plus potential royalties. The company retains an option to co-develop and co-promote in the United States, with both parties splitting U.S. profits and losses.
This partnership expansion demonstrates the success of Nurix's DEL-AI discovery platform in developing innovative drugs for previously undruggable targets, while providing non-dilutive capital and pipeline expansion opportunities.
Nurix Therapeutics (NRIX) announced its upcoming participation at the AACR 2025 Annual Meeting in Chicago, presenting research through two oral and two poster presentations. The company will showcase preclinical data from its DEL-AI platform and several degrader programs.
The oral presentations will focus on: 1) DEL-AI's proteome-wide in silico screening using machine learning foundation models, and 2) selective, orally bioavailable Aurora A degraders for cancer treatment. The poster presentations will highlight: 1) NRX-0305, a pan-mutant BRAF degrader showing broad preclinical efficacy and brain penetrance, and 2) NX-5948, a CNS-penetrant catalytic BTK degrader that challenges conventional CNS drug design principles.
Nurix Therapeutics (NRIX) announced that its drug bexobrutideg (NX-5948) has received Orphan Drug Designation (ODD) from the FDA for treating Waldenström macroglobulinemia (WM). Bexobrutideg is an oral, brain-penetrant BTK degrader currently in Phase 1a/b clinical trials for relapsed/refractory B-cell malignancies.
The ODD grants several benefits including tax credits for clinical testing, FDA fee waivers, and seven years of market exclusivity upon approval. The drug represents a new class of targeted protein degraders, marked by the novel 'deg' suffix, distinguishing it from traditional inhibitors that use the 'ib' suffix.
The designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia. The drug's mechanism involves catalytic degradation of target proteins through the proteasome, potentially eliminating mutant oncoproteins resistant to inhibitor therapy.
Nurix Therapeutics (NRIX) has granted inducement awards to 13 new employees on March 11, 2025, as approved by the company's Compensation Committee under Nasdaq Listing Rule 5635(c)(4). The awards include:
- Stock options to purchase 157,150 shares with a 10-year term and $13.90 exercise price
- Restricted stock unit awards (RSUs) representing 107,500 shares
The stock options vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. RSUs also vest over 4 years, with 25% vesting on April 30, 2026, and the remainder vesting quarterly. Both awards require continued employment with Nurix for vesting.
Nurix Therapeutics (Nasdaq: NRIX) has appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D. to its board of directors. Dr. Baynes, currently executive vice president and chief medical officer of Eikon Therapeutics, brings over 22 years of clinical leadership experience in pharmaceutical and biotech companies.
Previously serving as chief medical officer at Merck, Dr. Baynes supervised the clinical portfolio and developed strategies for numerous medicines, including pembrolizumab (Keytruda). He has been a member of Nurix's Medical Advisory Board since 2023 and has expressed particular interest in the company's protein degradation science and clinical trials of NX-5948 in patients with CLL and Waldenström macroglobulinemia.
Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines for cancer and inflammatory diseases, has announced its participation in two major investor conferences in March 2025.
The company's leadership, including President and CEO Arthur T. Sands, M.D., Ph.D., and CFO Hans van Houte, will attend the Jefferies Biotech on the Beach Summit in Miami Beach for one-on-one meetings on March 11, 2025. They will also participate in the Barclays 27th Annual Global Healthcare Conference in Miami Beach, featuring a fireside chat on March 12, 2025, from 10:00-10:25 a.m. ET.
The fireside chat will be accessible through a live webcast on the Investors section of Nurix's website, with the recording available for 30 days following the event.
